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Abstract 
 
A RANDOMIZED TRIAL OF BILEVEL POSITIVE AIRWAY PRESSURE 
DEVICE AND HIGH FLOW OXYGEN FOR PERSISTENT DYSPNEA IN  
ADVANCED CANCER PATIENTS 
Publication No.________* 
 
David Hui, BSc, MSc, MD, FRCPC 
 
Supervisory Professor: Eduardo Bruera, MD 
 
Background: Dyspnea is a common and distressing symptom among 
patients with advanced cancer.  The role of bilevel positive airway pressure 
(BIPAP) and Vapotherm in the relief of dyspnea have not been well defined.   
We aimed to determine and to compare the efficacy of BIPAP and 
VapoTherm for cancer related dyspnea. 
Methods: In this randomized, open-label, crossover study, we randomly 
assigned advanced cancer patients with persistent dyspnea ≥3/10 to either 
Vapotherm for 2 hours followed by BiPAP for 2 hours, or BiPAP followed by 
Vaptherm.  A variable washout period was instituted between interventions. 
The primary end point was change in numeric rating scale before and after 
each intervention.   We planned to enroll 50 patients in total. 
Results: Among the 803 patients screened over the last 8 months, 62 (26%) 
were eligible, and 16 (2%) were enrolled so far.  Five patients completed the 
entire study successfully, 4 discontinued the study prematurely due to 
prolonged relief of dyspnea, and 7 dropped out for various reasons, including 
v 
inability to tolerate BIPAP (N=3), anxiety (N=2), fatigue (N=1) and pain 
requiring opioids (N=1).  The median baseline numeric rating score for 
dyspnea was 7/10 (interquartile range (IQR) 5-8), and the median baseline 
Borg score was 4/10 (3-7).  Interim analysis revealed that BIPAP was 
associated with a median change in numeric rating score of -3 (N=10, IQR     
-6.3 to -1, p=0.007) and modified Borg score of -1 (N=10, IQR -3 to 0.3, 
p=0.058), while Vapotherm was associated with a median change in numeric 
rating score of -2 (N=9, IQR -3 to -1, p=0.011) and modified Borg score of      
-2.5 (N=8, IQR -5.5 to -0.1, p=0.051).  Among the 5 individuals who 
completed the entire study, 2 preferred Vapotherm, 2 favored BIPAP, and 1 
liked both.  The respiratory rate decreased and the oxygen saturation 
improved with both interventions.  No significant toxicities were observed. 
Conclusions: We were successfully able to enroll patients onto this clinic 
trial.  Our preliminary results suggest that BIPAP and Vapotherm are highly 
efficacious in providing relief for patients with persistent refractory dyspnea.  
A direct comparison of the two interventions will be done upon study 
completion.  Further research is necessary to confirm our findings. 
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Chapter 1. Introduction 
A. Background 
Dyspnea is a subjective awareness of difficulty breathing, which may be 
associated with the distressing sensation of suffocation.  It is one of the 
most common and most feared symptoms among cancer patients, 
occurring in approximately 20-40% of patients at the time of diagnosis of 
advanced disease (1, 2), and increases up to 50-70% in the last 6 weeks 
of life (3).   Dyspnea has also been shown to be an important prognostic 
factor for patients with advanced cancer (4, 5). 
 
The pathophysiology of dyspnea is shown in Figure 1 (6).  Causes of 
dyspnea can be classified as cancer-related, treatment-related and 
psychological factors.  Progressive disease may result in parenchymal 
metastasis, lymphagitic carcinomatosis, airway obstruction, atelectasis, 
and/or pleural effusion causing difficulty breathing.  Complications of 
cancer, including thromboembolism, pneumonia, sepsis and anemia of 
chronic disease may also contribute to the sensation of breathlessness.  
Cancer patients also tend to have poor respiratory reserve because of 
chronic obstructive pulmonary disease (COPD) and/or prior lung 
resections, predisposing them to the development of respiratory 
symptoms.  In advanced cancer patients with significant cachexia, 
dyspnea may also be related to loss of respiratory muscles, an under-
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recognized etiology (6).  In a small proportion of patients, no identifiable 
etiologic factors can be found. 
 
Current management of dyspnea involves treatment of any reversible 
causes and supportive measures to minimize the sensation of dyspnea.  
Relief of dyspnea can be achieved by a number of pharmacologic and 
non-pharmacologic measures.  Common medications for dyspnea include 
opioids, bronchodilators, corticosteroids and benzodiazepines.  Opioids 
had proven palliative benefit for dyspnea.  In a cross over study with 10 
cancer patients, Bruera et al. showed that subcutaneous morphine was 
more effective at relieving dyspnea compared to placebo 60 minutes after 
drug administration (7).  A systemic review suggested that oral and 
parenteral, but not nebulized, opioids as effective in managing dyspnea 
(8).  However, the potential benefit with opioids is limited by its toxicity 
profile, particularly sedation and opioid induced neurotoxicity at higher 
doses.  Even with high doses of opioids and other supportive measures, 
some patients continue to experience severe dyspnea. 
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Figure 1. Pathophysiology of Dyspnea and Potential Mechanisms of 
Action of Supplemental Oxygen and BIPAP.  The sensory cortex 
receives afferent input from mechanoreceptors in airways and chest wall, 
stretch and irritant receptors in lungs, chemoreceptors in brainstem, and 
other signals from the motor cortex, generating the sensation of 
breathlessness.  Supplemental oxygen can improve the arterial oxygen 
level, reducing the level of chemoreceptor activation, and thus the 
sensation of dyspnea.  BIPAP not only improves oxygenation, but also 
exerts a mechanical effect on the airways and chest wall, which in the 
process improves ventilation, work of breathing, and potentially dyspnea.  
 
Non-pharmacologic measures such as supplemental oxygen has been 
shown to be beneficial for patients with hypoxemia, although its role in 
dyspneic patients who are not hypoxemic remains unresolved (9).  A 
prospective, double-blind crossover trial included 14 advanced cancer 
patients, and found significant improvements in dyspnea comparing 
Chemoreceptors 
↓ PaO2 
↑ PaCO2 
Mechanoreceptors 
J receptors 
Irritant receptors 
Barorceptors 
∆ airway, lung,  
PA pressure 
↑ respiratory muscle use 
Chest wall receptors 
Supplemental 
Oxygen (e.g. 
Vapotherm) 
Bilevel Positive 
Airway Pressure 
(BIPAP) 
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oxygen to room air by mask (10).  However, a larger study with 33 patients 
did not confirm this benefit (11).  The observation that supplemental 
oxygen therapy only benefits patients with hypoxemia suggests that 
improved oxygenation is only part of the equation for relief of dyspnea.  In 
recent years, high-flow oxygen delivery devices (VapoTherm) and bilevel 
positive airway pressure (BIPAP) have become available for treatment of 
acute or chronic respiratory distress, although their potential for relief of 
dyspnea in the palliative care population remains to be tested.   
 
VapoTherm is a high flow heat and humidification device that can deliver 
oxygen of up to 40 L/min via nasal prongs.  Studies on VapoTherm have 
so far focused on patients with acute exacerbations of COPD and 
congestive heart failure (CHF).  A randomized crossover study of 
Vapotherm by nasal prongs versus supplemental oxygen by non-
rebreather mask in 14 COPD patients showed equivalent efficacy in terms 
of oxygen delivery, but Vapotherm was better tolerated (12).  Another 
study of 5 COPD patients compared high flow versus low flow oxygen via 
Vapotherm.  The high flow oxygen arm was associated with a trend 
towards decreased dyspnea by both numeric rating scale and Borg scale 
(13). 
 
BIPAP is a form of non-invasive positive pressure ventilation (NIPPV), and 
represents another attractive option for relief of dyspnea using pre-set 
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inspiratory pressure that allows patient to control not only the breathing 
rate but also the duration of inspiration (14).  It is commonly used for 
treatment of acute respiratory failure, including exacerbations of COPD 
(15) and CHF (16).  Intermittent BIPAP has been studied in the critical 
care setting for immunocompromised cancer patients who developed 
pneumonia, and has been demonstrated to reduce the need for intubation, 
serious complications, and mortality (17). 
 
In the chronic respiratory failure setting, the use of BIPAP has been mostly 
limited to patients with neuromascular disorders such as amyotrophic 
lateral sclerosis (ALS) (18) and Ducheene muscular dystrophy (19) (Table 
1).  One study included 20 ALS patients randomized to long term BIPAP 
or best supportive care, and found significant survival and satisfaction in 
the BIPAP arm (20).  A review of 276 patients with chronic respiratory 
failure from various causes found that BIPAP was associated with 
improved gas exchange and decreased hospitalization (21). 
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Table 1. Key Studies of Non-Invasive Positive Pressure Ventilation in 
Patients with Advanced Respiratory Failure 
 
Population Design NIPPV 
settings 
Intervention period 
ACUTE RESPIRATORY FAILURE IN ADVANCED STAGES OF DISEASE 
Benhamou et 
al. 1992 (22) 
Acute on chronic 
resp. failure 
(COPD, RLD, 
bronchiectasis), 
elderly 76±8 yrs 
Prospective 
N=30 
NR Daily schedule: 
continuous first 12h, then 
intermittent days and 
continuous nights 
Total: 11.4 days 
Freichels et 
al. 1994 (23) 
Acute on chronic 
resp. failure 
(cancer, COPD, 
restrictive).  High 
PaCO2 
Retrospective 
case series N=3 
NR Daily schedule: 
continuous with 1 to 2 
hours off mask  
Hilbert et al. 
2001 (17) 
Acute resp. failure 
(Immunocompromi
sed cancer 
patients)  
Randomized trial 
on intermittent 
BIPAP or supp 
O2  N=52 (26) 
IPAP: 15±2 
cmH2O 
EPAP: 6±1 
cmH2O 
Daily schedule: 
intermittent 
45 min up to 3h  
Total: 6±3 days 
 
Levy et al. 
2004 (24) 
Acute resp. failure 
who were DNI  
Prospective 
cohort study 
N=114 
IPAP: 13±3 
cmH2O 
EPAP: 5.3±1 
cmH2O 
Daily schedule: 
continuous with 
intermittent breaks 
Total: 13.2 ±2.4h  
 
Schettino et 
al. 2005 (25) 
Acute on chronic 
resp failure (COPD, 
CHF, advanced 
cancer) who were 
DNI 
Prospective 
observational 
study 
N=131 (40 
cancer) 
NR Daily schedule: 
continuous.  Parameters 
recorded +2 h, then q12h 
Total: 2 days 
CHRONIC RESPIRATORY FAILURE 
Legar et al. 
1994 (21) 
Chronic resp. 
failure (COPD, 
kyphoscoliosis, 
muscular 
dystrophy) on 
NIPPV 
Retrospective 
case series 
N=276 
NR Daytime: 1.5±2h 
Nighttime: 9±2h 
Total: 6 months 
 
Pinto et al. 
1995 (20) 
Chronic resp. 
failure (ALS) 
Quasi 
randomized trial 
N=20 (10) 
NR NR 
Lyall et al. 
2001 (26) 
Chronic resp. 
failure (ALS) 
Prospective case 
control N=16 
NR Daytime: as needed 
Nighttime: continuous 
Total: 6 months 
REVIEW 
Nava et al. 
2004 (27) 
Review of NIPPV in 
cancer patients 
NA NA Gas exchange, pH, RR, 
dyspnea usually improve 
in 1-3 hours 
Abbreviations: ALS, amyotrophic lateral sclerosis; DNI, do not intubate; 
EPAP, expiratory positive airway pressure; IPAP, inspiratory positive 
airway pressure; NA, not applicable; NIPPV, non-invasive positive 
pressure ventilation; NR, not reported; RR, respiratory rate 
  7 
B. Study Rationale 
Patients with advanced cancer commonly experience dyspnea.  Current 
treatment options, such as supplemental oxygen, opioids and 
bronchodilators, provide limited relief of this distressing symptom, with 
many patients still experiencing persistent dyspnea.  One of the limitations 
of the current method of supplemental oxygen delivery is that it is 
cumbersome and uncomfortable.  The maximum rate delivered via nasal 
prongs is only 6 L per minute.  Patients with higher oxygen requirements 
have to wear a non-rebreather mask, which can deliver oxygen of up to 15 
L per minute (and up to 21 L per minute with the additional oxygen 
delivery by nasal prongs).  However, the mask may create a subjective 
sensation of suffocation or claustrophobia for patients. These 
impracticalities, coupled with its limited effectiveness in relief of dyspnea, 
raises the need for newer modalities of oxygen delivery that can be more 
successful in managing dyspnea.  Vapotherm and BIPAP represent two 
novel therapeutic options for patients with acute and chronic respiratory 
failure, although their efficacy in the palliation of dyspnea remains to be 
tested. 
 
Vapotherm represents a potentially attractive option for treatment of 
dyspnea because it can provide heated, humidified high flow oxygen (up 
to 40 L/min) through nasal prongs.  The effect of high flow oxygen on the 
relief of dyspnea has not been studied in detail, particularly in patients with 
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persistent dyspnea despite standard oxygen therapy.  Postulated 
mechanisms of how Vapotherm provides relief for dyspnea include (1) the 
ability to maintain a high level of PaO2 which has a direct effect the 
perception of dyspnea, (2) stimulation of trigeminal nerve, and (3) the 
ability to increase positive end expiratory pressure (PEEP). 
 
BIPAP may provide additional benefit to supplemental oxygen therapy 
(Figure 1).  BIPAP not only assists ventilation, but also increases 
inspiratory flow rate, corrects hypoventilation, resets central respiratory 
drive, increases exercise capacity, and unloads respiratory muscles (27-
29).  The last reason is of particular interest for advanced cancer patients 
who have dyspnea secondary to loss of respiratory muscles.  However, 
the potential benefit of BIPAP needs to be balanced against the discomfort 
associated with the mask.  We believe that some patients would prefer 
this modality despite the use of facial/nasal mask if it proved to be able to 
effectively improve dyspnea. 
 
A study investigating the effect of Vapotherm and BIPAP on persistent 
dyspnea would provide preliminary data regarding the feasibility and 
efficacy of these non-invasive assist devices for alleviation of 
breathlessness using a crossover, rather than parallel design.  A 
crossover design is specifically chosen for this study as it allows patients 
to determine their overall preference after a trial of both interventions.  
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Findings from this feasibility study, such as adherence, cross over period 
and outcome measures, could help us to design a larger crossover trial 
powered to examine differences in efficacy between these two 
interventions.  Our long-term goal is to improve the quality of life and care 
of patients with advanced cancer who experience the distressing symptom 
of dyspnea. 
 
C. Hypotheses 
We hypothesize that both intermittent BIPAP and Vapotherm are effective 
in the treatment of persistent dyspnea despite standard supplemental 
oxygen therapy in advanced cancer patients.   
 
We also postulate that BIPAP is more effective at relieving dyspnea (by 
numeric rating scale, Borg Scale, global assessment and washout period) 
than high flow oxygen therapy for patients who can tolerate this treatment, 
through the added benefits of improving inspiratory flow rate, alveolar 
recruitment, chest wall expansion. 
 
We further hypothesize that BIPAP can improve ventilation better than 
Vapotherm. 
 
D. Study Objectives 
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1. To determine the effects of BIPAP and VapoTherm on the severity of 
dyspnea compared to baseline as measured by the Numeric rating 
scale and the Borg scale. 
 
2. To compare the effects of BIPAP and VapoTherm on the severity of 
dyspnea compared to baseline as measured by the Numeric rating 
scale and the Borg scale. 
 
3. To determine the effects of BIPAP and VapoTherm on physiologic 
parameters, including heart rate, respiratory rate, blood pressure and 
oxygen saturation, and transcutaneous carbon dioxide level. 
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Chapter 2. Patients and Methods 
A. Study Design 
This is an open-label, randomized, crossover study involving VapoTherm 
and BIPAP for patients with cancer-related dyspnea (Figure 2).  Eligible 
patients who agreed to participate were randomized to receive either 
BIPAP or VapoTherm for 2 hours in the first treatment phase, followed by 
a variable washout period (up to 1 hour) and then either VapoTherm or 
BIPAP for 2 hours in the second treatment phase.  Because of the nature 
of study interventions, blinding was not possible.  
 
This study focused on patients with cancer-related dyspnea, which is 
defined as dyspnea predominately related to the underlying malignancy, 
with or without other secondary chronic respiratory diseases (e.g. COPD, 
asthma, idiopathic pulmonary fibrosis).  Potential pathologies may include, 
but not limited to, pulmonary parenchymal metastasis, lymphangitic 
carcinomatosis, pleural effusion, and significant cachexia with respiratory 
muscle weakness.    
 
A crossover design was utilized such that each participant had the 
opportunity to try both Vapotherm and BIPAP.  At the end of the study, 
he/she provided feedback regarding his/her overall preference through a 
survey directly comparing the two interventions in terms of dyspnea relief 
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and comfort.  This intra-individual comparison would not have been 
possible with a parallel design. 
Figure 2. Study Overview.  In this open-label, randomized, crossover 
study, advanced cancer patients with persistent dyspnea were 
randomized to either BIPAP followed by VapoTherm, or VapoTherm 
followed by BIPAP.  The total study duration was up to 5 hours.  Four 
assessments (before and after each intervention) were conducted during 
the study period, with a preference survey at the end. 
 
B. Inclusion Criteria 
1. History of advanced cancer, defined as locally advanced, recurrent or 
metastatic disease  
2 hours 
R 
BIPAP 
VapoTherm 
VapoTherm 
BIPAP 2 hours 
Assessment 1 
Assessment 2 
Assessment 4 
Eligible Patients 
• Advanced cancer inpatient 
• Dyspnea at least 3 out of 10 at rest within last 2 
week despite supplemental oxygen for at least 1 hour 
Assessment 3 
Variable washout period  
(up to 1 hour)* 
Preference Survey 
Baseline 
* Back to same oxygen level prior to study.  Patient may proceed to the next intervention 
when they have a dyspnea score ≥ baseline level - 1, or have a dyspnea score of ≥3 by the 
end of 1 hour. 
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2. Patients with persistent dyspnea, defined in this study as dyspnea at 
rest with an average intensity level ≥3 out of a Numeric rating scale 
from 0 to 10 for at least 2 week and just prior to study initiation, despite 
supplemental oxygen of up to 21 L/min to keep oxygen saturation 
≥90% 
3. Dyspnea is judged clinically to be predominantly due to underlying 
malignancy, with or without obstructive lung disease 
4. Inpatient at M.D. Anderson Cancer Center 
5. Patients with cancer treatment related dyspnea are eligible for this 
study if they meet the eligibility criteria above 
6. Able to communicate in English 
7. Expected life expectancy >1 week 
8. Patients with a diagnosis of pneumonia and/or pulmonary embolism 
are also eligible for this study if they meet the eligibility criteria above, 
with dyspnea ≥2 weeks prior to the diagnosis of pneumonia 
 
C. Exclusion Criteria 
1. Patients who remain hypoxic (i.e. O2 saturation <90% despite maximal 
oxygen delivery (21 L/min) are not included in this study because they 
are considered to have severe life-threatening respiratory failure and 
are too unstable for study inclusion. 
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2. Hemodynamic instability (heart rate>140 beats/minute, systolic blood 
pressure <80mmHg) within 24 hours of study initiation (as per Clinic 
Station) 
3. Acute respiratory distress requiring intubation 
4. Delirium as indicated by a Memorial Delirium Assessment Scale 
(MDAS) of 13 or higher 
5. Glasglow coma scale <8 
6. Excessive airway secretions interfering with BIPAP administration 
7. History of facial trauma within 1 month of enrollment 
8. Upper GI bleed within 2 weeks or esophageal rupture of enrollment 
9. Partial or complete small bowel obstruction or severe nausea/vomiting 
(ESAS nausea >7/10) within 48 hours of enrollment 
10. Hemoglobin <8 g/dL at the time of enrollment (blood draw within last 2 
weeks) 
11. Acute exacerbation of COPD or CHF within 2 weeks of enrollment by 
history or physical 
12. Unwilling to provide informed consent 
13. Diagnosis of non-cancer related dyspnea (e.g. COPD, CHF or any 
chronic respiratory disease) requiring supplemental home oxygen prior 
to hospitalization. 
 
D. Patient Screening and Recruitment 
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Newly admitted advanced cancer patients who were potentially dyspneic 
were identified through multiple sources, including a daily log of inpatients 
initiated on supplemental oxygen or nebulizer treatments the previous day 
by respiratory therapy, advanced nurse practitioners from rehabilitation 
medicine and thoracic medicine, fellows from the palliative care and other 
collaborators.    
 
Initial screening was conducted using Clinic Station.  Based on information 
from this electronic health record interface, we excluded patients who 
were discharged, died, hemodynamically unstable, or had a diagnosis of 
curable cancer, COPD exacerbation, CHF exacerbation, small bowel 
obstruction, facial trauma or upper GI bleed. 
 
If patients appeared eligible after initial screening, they were approached 
for study enrollment by our research staff, usually within 24 hours.  A two-
stage consent process was utilized by first asking patients for their 
permission to screen them for study eligibility.  Patients who met all 
eligibility criteria were then provided with further information including the 
informed consent form, and were invited to participate in this study.   
 
E. Study Interventions 
Vapotherm: The Vapotherm 2000i Respiratory Therapy Device was 
used (Vapotherm, Stevensville, MD, USA).  It was approved by the U.S. 
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Food and Drug Administration (FDA) in 2001 (K042245) to “add moisture 
to and to warm breathing gases for administration to patients, including 
neonates/infant, pediatrics, and adults.  The environment of use include 
home, hospital or sub-acute institutional settings”.  Patients on the 
Vapotherm arm received high flow oxygen via nasal prongs.  FiO2 was set 
at 100% throughout the intervention period.  The level of heat (between 
35° and 37°) and oxygen flow (between 10 L/min and 40 L/min) were 
adjusted initially by our study respiratory therapist to minimize dyspnea 
while keeping the patient comfortable. 
 
BIPAP: The BIPAP Vision Ventilatory Support System was used 
(Respironics Inc.  Murrysville, Pennsylvania, USA).  It was approved by 
the FDA in 1998 (K982454) for “spontaneously breathing adult patients 
suffering from acute respiratory failure, acute or chronic respiratory 
insufficiency, or obstructive sleep apnea in hospitals, or other institutional 
settings, under the direction of a physician”.  Patients assigned to receive 
BIPAP treatment received non-invasive ventilation delivered through a 
face or nasal mask.  Patients were given a choice of either a ResMed 
Latex Free Hospital Nasal Mask R611-735/1 (ResMed Ltd, Bella Vista, 
NSW, Australia) or a ResMed Latex Free Hospital Full Face Mask R143-
340/5 (ResMed Ltd, Bella Vista, NSW, Australia).  The mask was adjusted 
and connected to a ventilator set in pressure support mode (S/T).  To 
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minimize discomfort, the system used in this study was leak-tolerant, so 
that the mask would not need to be airtight. 
 
After securing the mask, the level of support was started at an inspiratory 
pressure of 8 cm of H2O and expiratory pressure of 5 cm of H2O.  The 
pressures was progressively increased and adjusted to maximize 
alleviation of dyspnea and to minimize discomfort, with a target inspiratory 
pressure between 8 and 18 cm of H2O, and target expiratory pressure 
between 3 and 10 cm of H2O.  The FiO2 was kept at 100% throughout the 
intervention period. 
 
F. Intervention Duration 
One small randomized study of high flow and low flow oxygen via 
VapoTherm demonstrated a trend towards improved dyspnea with the 
high flow arm after 30 minutes of intervention.  The minimal time for 
clinical improvement of dyspnea using BIPAP is not clear from existing 
literature.  However, a number of studies have shown improved 
oxygenation and physiologic parameters within 1 to 3 hours (Table 1).  
Thus, we chose a 2 hour period for each intervention, which should give 
patients enough time to derive some treatment benefits. 
 
G. Study Process 
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Once the patient signed the informed consent and the patient’s attending 
physician was notified, the study interventions were initiated within 24 
hours. A standing order regarding BiPAP, Vapotherm and medication use 
during the study was placed in the patient’s chart to inform clinical staff of 
this study.  Clinical nurses caring for the patient were also given further 
study information.  A randomization list was prepared by our study 
biostatistician for each stratum in advance.  
  
During the study period (up to 5 hours), our research staff conducted 
study assessments at 4 time points (Figure 2), and provided close 
monitoring.  Patients who could not tolerate an intervention because of 
discomfort were offered the opportunity to (1) temporarily halt the 
intervention and resume when ready, (2) switch to alternative intervention 
after a variable washout period (if it has not been tried), or (3) discontinue 
the study.   Patients who deteriorated clinically during the study (e.g. 
severe respiratory distress, oxygen saturation decreased to <90%, 
decreased mental status, hemodynamic instability) or required 
breakthrough opioid had to terminate the study prematurely.   
 
At the end of study, patients were offered the opportunity to choose to 
remain on BIPAP, Vapotherm or return to standard supplemental oxygen 
therapy.  We did not provide any followup or monitoring after completion of 
study. 
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H. Washout Period 
While the effect of gas exchange is rapid and not expected to carry over 
significantly, the duration of washout period for patients to return to 
baseline level of dyspnea after using these interventions has not been 
defined.  Our group has previously conducted a number of crossover trials 
for dyspnea in advanced cancer patients, comparing parenteral vs. 
nebulized opioids (30), and air vs. oxygen supplementation (10, 31).  The 
washout periods were relatively short (0-60 minutes) due to the rapid 
nature of gas exchange.  No clinical trials have directly compared both 
BIPAP and Vapotherm.  Among the few crossover trials involving either of 
these interventions, the washout period varied from 0-10 minutes for 
BIPAP (32, 33) to 60 minutes for Vapotherm (12).  Thus, we felt that a 
variable wash out period of up to 60 minutes was reasonable for this 
feasibility study. 
 
We introduced a variable washout period between the two interventions to 
determine the optimal duration required for patients to return to baseline 
dyspnea level, which was defined as greater than or equal to the dyspnea 
level on Numeric rating scale just prior to starting study minus 1.  For 
instance, if a patient had dyspnea rating of 5/10 prior to study, then any 
score of 4 or above was considered to be back to baseline.  During the 
washout period, patients were given the same level of supplemental 
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oxygen just prior to study initiation.  For patients whose dyspnea had not 
returned to ≥baseline -1 level at the end of 1 hour, they were able to 
proceed to the next intervention only if dyspnea ≥3/10.  However, if their 
dyspnea level remained <3/10 at the end of 1 hour, they would not be 
eligible to proceed to the next intervention.   
 
Patients were asked about their level of dyspnea on a numeric rating scale 
every 10 minutes after they have completed the first intervention for up to 
1 hour.  This allowed us to determine the time for dyspnea to develop, and 
whether there is any significant difference between VapoTherm and 
BIPAP.  To minimize bias in this measurement, patients were only told 
that a waiting period of up to 1 hour was required to start the next 
intervention, but not the requirement that they need to return to baseline to 
proceed.   
 
I. Medication Use 
Medications such as opioids, steroids and bronchodilators could have an 
effect on dyspnea, and could affect the findings of this study if given 
around the study period.  While it would be ideal to minimize these co-
interventions by ensuring that patients are on stable doses of medications 
before starting the study, inpatients have frequent medication changes 
during the hospitalization making it difficult to control this factor. 
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To minimize the effect of opioids, steroids and bronchodilators on the 
measurement of dyspnea during the study, patients who were receiving 
scheduled and/or breakthrough doses of these medications for any 
indications would need to wait for a short duration prior to initiating study 
interventions, defined in this study as at least 1 hour for opioids and 
steroids, and 30 minutes for bronchodilators prior to study initiation as pre-
study dose.  Patients receiving continuous opioid infusion by patient 
controlled analgesia pump were able to enroll onto the study if they have 
not required breakthrough doses for at least 1 hour. 
 
During the study period (up to 5 hours), patients who required any 
breakthrough opioids (parenteral, oral, inhaled), breakthrough steroids 
(parenteral, oral or inhaled) or scheduled/breakthrough bronchodilators 
were considered as dropouts, and the study interventions were 
discontinued.  Patients could continue to receive scheduled doses of 
opioids and steroids during the study period. 
 
J. Study Outcome Measures 
This study included 4 main assessments—before and after each of the 
two interventions (Figure 2 and Table 2).  All study assessment forms can 
be found in Appendix A. 
  22 
 
Table 2. Study Outcome Measures 
Assessment Items First 
assessment 
Second 
assessment 
Third 
assessment 
Fourth 
assessment 
Demographic variables/Baseline ×    
Medication history ×    
MDAS ×    
ECOG performance status ×    
Physical including weight ×    
Cancer Dyspnoea Scale ×    
Numeric Rating Scale × × × × 
Modified Borg scale × × × × 
Adverse events × × × × 
Vitals ×× ×× ×× ×× 
Continuous TCCO2 monitoring ×× ×× ×× ×× 
Continuous oximetry monitoring ×× ×× ×× ×× 
Respiratory settings × × × × 
Duration of intervention  × × × 
Global symptom evaluation  ×  × 
Preference survey    × 
Study satisfaction questions    × 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MDAS, 
Memorial Delirium Assessment Scale; TcCO2 transcutaneous carbon 
dioxide 
x = one measurement, xx = heart rate, respiratory rate, TcCO2, and O2 
saturation were recorded every 30 minutes during each intervention by 
using the trend function 
 
1. Baseline Patient Characteristics  
Baseline demographics were collected from the patient and/or health 
records just prior to initiation of first intervention, and included the 
following: 
• Demographics (date of birth, gender, race) 
• Cancer diagnosis (date of diagnosis, cancer type, treatments received) 
• Comorbidities (chronic pulmonary or cardiac conditions such as 
COPD, CHF, bronchiectasis) 
• Medications 
• Previous BIPAP/Vapotherm use (number of times, most recent use) 
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• Primary etiology of dyspnea 
• Dyspnea measures (see below for details) 
• To better characterize the dyspnea at baseline, we also used the 
Cancer Dyspnoea Scale, a validated 12 item questionnaire specifically 
designed to assess the quality of dyspnea in cancer patients (34).  
Each item has a score between 1 and 5, with a total score of up to 60, 
along with sub-scores for sense of effort, anxiety, and discomfort 
(Appendix A).   
• ECOG performance status at the time of study initiation.  This is a 
validated numeric rating scale with a score from 0 to 4 related to 
patient’s functional status (35), where 0=Fully active, able to carry on 
all pre-disease performance without restriction; 1=Restricted in 
physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work; 
2=Ambulatory and capable of all selfcare but unable to carry out any 
work activities. Up and about more than 50% of waking hours; 
3=Capable of only limited self care, confined to bed or chair more than 
50% of waking hours; 4=Completely disabled. Cannot carry on any 
selfcare. Totally confined to bed or chair 
• Memorial Delirium Assessment Scale (MDAS) is a 10 item 
questionnaire validated in cancer patients for assessment of delirium 
(36).  It can be administered by a physician, a nurse or a research 
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coordinator, assigning a score between 0 and 30.  A score of >13 is 
suggestive of delirium 
• Focused physical examination of the cardiorespiratory system, and 
included the vitals (heart rate, respiratory rate, blood pressure, oxygen 
saturation) as per standard clinical practice 
 
2. Dyspnea Measures 
Dyspnea is a subjective sensation experienced by patients.  The numeric 
rating scale (0=no dyspnea and 10=worst dyspnea) (37-39) and modified 
Borg scale (37-40)  are two of the most commonly used scales to assess 
the severity of dyspnea.  As there is no established gold standard for 
measurement of dyspnea, we used both scales in this study.   
 
The numeric rating scale is a 0 to 10 categorical scale validated for rating 
severity of dyspnea, with 0 denoting no dyspnea, and 10 representing 
worst dyspnea (37-39).  Patients were asked their level of dyspnea at the 
moment of assessment. 
 
The modified Borg scale represents another 0 to 10 categorical scale for 
rating the severity of dyspnea.  The Borg scale was initially developed to 
determine the sensation of exertion with exercise.  Overtime, it has been 
modified and validated for the assessment of dyspnea.  Although the 
range for both numeric rating scale and modified Borg scale is between 0 
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and 10, the two scales have different anchors and assess dyspnea 
differently.  The modified Borg scale has more descriptors throughout its 
range, and is designed as a ratio scale in which a rating of 2 represents 
half the degree of dyspnea as 4, which is in turn half as severe as 8 (37-
40). 
 
Both dyspnea assessments were performed immediately prior to initiation 
of first intervention (assessment 1), immediately before completion of first 
intervention (assessment 2), immediately before the second intervention 
(assessment 3) and immediately before completion of second intervention 
(assessment 4) (Figure 2).    
 
3. Toxicities 
While we did not expect significant side effects from Vapotherm or BIPAP, 
it was important to document any common or severe adverse effects.  
These included dry eyes, dry mouth, mask discomfort, feeling of 
suffocation, stomach bloating, anxiety, trouble eating, trouble drinking, 
trouble speaking and trouble sleeping.  Since many of these side effects 
were not captured in the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0, we developed a specific patient reported 
outcome form for this study in which patients were asked to rate their side 
effects from 0 (none) to 10 (worst). 
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4. Physiologic Measures 
At each of the four assessments, we determined the vital signs (heart rate 
(HR), respiratory rate (RR), blood pressure (BP), and oxygen saturation 
(O2 sat).  O2 saturation was monitored using the Alaris® SpO2 module- 
8200 series oximeter (Alaris Medical Systems, Cardinal Health-Alaris 
Products, San Diego, CA, USA).  Tissue PCO2 level was monitored using 
the Sentec Digital Monitoring System TCO2M® Transcutaneous Monitor, 
Novametrix Model #860 (Novametrix Medical Systems Inc., Wallingford, 
CT,  USA) placed on the skin over the face heated between 37°C and 
45°C (41-43). Blood gases were not performed to minimize patient 
discomfort. 
 
5. Device Settings 
The BIPAP and Vapotherm settings were documented by respiratory 
therapy.  BIPAP settings included mode, breath type, inspiratory oxygen 
(FiO2), respiratory rate, inspiratory pressure (IPAP), expiratory pressure 
(EPAP), and average tidal volume (VT).  Vapotherm settings included 
FiO2, oxygen flow and temperature. 
 
6. Global Symptom Evaluation and Patient Preference 
At the end of each intervention, patients were asked to provide a global 
assessment of the device on their breathing (worse, about the same, or 
better). If their answer was better, they were asked to rate how much 
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better their symptoms were (almost the same, hardly any better at all, a 
little better, somewhat better, moderately better, a good deal better, a 
great deal better, a very great deal better). If their answer was worse, they 
were asked to rate how much worse their symptoms were (almost the 
same, hardly worse at all, a little worse, somewhat worse, moderately 
worse, a good deal worse, a great deal worse, a very great deal worse).  
The global symptom evaluation can help provide an anchor for 
determining the minimal clinical important difference for the numeric rating 
scale and modified Borg scale.  A second independent part of this tool 
given out at the end of the study asked patients regarding their satisfaction 
with the study.  This tool has been used by various symptom researchers 
(44, 45). 
 
A preference survey was given to patients at the end of the study who 
tried both BIPAP and Vapotherm.  Subjects were asked to directly 
compare the two devices regarding dyspnea relief, comfort, overall choice. 
Given that no clinical trials have examined both BIPAP and Vapotherm, 
this survey was specifically designed for this study. 
 
K. Statistical Analyses 
Our primary outcome was to determine estimates of the magnitude of 
changes in dyspnea scores before and after each intervention, which 
would be compared using a crossover design. We planned to enroll 50 
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patients overall, with 25 patients receiving BIPAP first then Vapotherm 
second, and with 25 patients receiving Vapotherm first then BIPAP 
second). This would allow us to declare as statistically significant a 
difference in mean change scores of 0.6 standard deviations between 
treatment groups, assuming a two-sided significance level of 0.05 and 
80% power. Patients were expected to return to their approximate 
baseline score between treatments. 
 
For the purpose of this thesis, the interim data for 16 patients enrolled so 
far were analyzed.  Descriptive statistics (e.g. means, medians, standard 
deviations) were used to describe the preliminary findings regarding 
dyspnea scores, adverse effects, vitals and overall preference, and to 
minimize repeated comparisons.  The paired Student’s t-test was used to 
compare continuous variables (e.g. vitals) before and after each 
intervention, and the paired Wilcoxon test was used for non-parametric 
variables (e.g. numeric rating scale, modified Borg scale and adverse 
effects). Upon completion of accrual (i.e. 50 subjects), we would be able to 
conduct a more detail statistical analysis to directly compare the findings 
between Vapotherm and BIPAP.  The Statistical Package for the Social 
Sciences (SPSS version 16.0, SPSS Inc., Chicago, Illinois) software was 
used for statistical analysis.   
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Given the preliminary nature of this analysis, we combined all results 
related to BIPAP use from both treatment arms, and also all results related 
to Vapotherm use from both treatment arms.  In the final analysis, the 
results would be analyzed in a crossover fashion if there was no 
significant period effect. 
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Chapter 3. Study Process 
While study design is the most critical part of the research process, the 
success of a clinical trial depends on many other factors, including 
coordination of study process, commitment and training of research staff, 
meticulous data management, satisfactorily addressing the regulatory 
aspects of this study, and appropriate resource allocation.  This chapter 
aims to highlight some of the operational aspects of this clinical trial. 
 
A. Study Protocol and Institutional Approval 
The study protocol writing process took approximately 4 months between 
October and February 2009, with input from Dr. Bruera, Dr. Hui, Dr. Price 
from Critical Care, Dr. Faiz for Pulmonary Medicine, Clarence Finch and 
Laura Withers from Respiratory Therapy, and Dr. Palmer from 
Biostatistics.  After multiple revisions, it was submitted and eventually 
approved by the Clinical Research Committee at M.D. Anderson Cancer 
Center on April 8, 2009.  This was subsequently approved by the 
institutional review board on July 24, 2009.  A copy of the study consent is 
provided in the Appendix B.  The study was formally activated on August 
11, 2009. This clinical trial was registered at ClinicalTrials.gov (registration 
number NCT00934128). 
 
B. Standard Operating Procedure 
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A 12-page standard operating procedure was created shortly before study 
activation.  This study manual outlined each of the steps involved in this 
study, and defined the specific role for research physician, coordinator and 
respiratory therapist (Appendix C).  This important document helped to 
provide orientation to research staff members, to standardize the study 
procedures and to improve communication between team members.   
 
C. Research Team 
The research team consisted of a research coordinator, two respiratory 
therapists and a research fellow (Dr. Hui).  Dr. Bruera oversaw the 
operation of this study, along with the research nurse manager and head 
of respiratory therapy.   
 
During the month before and the month after study activation (July to 
September 2009), we focused on ensuring all research staff were 
comfortable with the study process, optimizing the study forms, and 
identifying potentially eligible patients.  Multiple training sessions were 
provided to help familiarize each research team member with his/her role 
and to improve overall coordination. Training consisted of didactic lectures 
with Powerpoint presentations as well as practical mock sessions.   All 
members were provided with a copy of the standard operating procedure.  
Moreover, Dr. Hui provided one-on-one training for our research 
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coordinator on a daily basis for two months to optimize the patient 
enrollment process. 
 
The research team met regularly during research meetings (once every 1-
2 weeks) to discuss issues related to the screening and recruitment 
process, study assessments, data monitoring and trouble shooting.  
Minutes were kept and sent out to team members with action list items to 
ensure accountability. 
 
D. Patient Accrual and Trouble Shooting 
One of the major challenges of this study related to patient accrual.  
Before study activation, Dr. Hui presented at the Critical Care 
departmental meeting, palliative care departmental meeting, and 
respiratory therapy team meetings to promote this study.   
 
We initially relied predominantly on clinical respiratory therapists to 
provide us with names of patients who may be dyspneic.  However, we 
soon realized that this referral process had limited success, likely due to 
the fact that clinical respiratory therapists are generally unfamiliar with 
clinical trials.  The palliative care team referred patients regularly, although 
those patients were generally too ill for enrollment.  In October 2009, we 
started receiving an automated list of patients who were newly started on 
oxygen therapy or nebulizer treatments throughout the hospital.  We also 
  33 
engaged the advanced nurse practitioners from Thoracic Medicine and 
Rehabilitation Team, who started to make regular referrals.   
 
To improve accountability and participation, we sent out e-mails once to 
twice a week to referring sources to update them regarding any progress 
in recruitment, and to encourage further referrals.   Since October 2009, 
this study has been able to consistently enroll patients. 
 
E. Data Management 
We created a tracking Excel database to facilitate daily screening of 
potentially eligible patients.  This tracking database consisted of patient 
medical record numbers, date of referral, source of referral, patient 
location, reasons for ineligibility or refusals (if applicable).  It provided an 
up-to-date summary of patient recruitment. 
 
An Access database was created by our departmental data analyst to 
record information captured in this study.  Data were entered in this 
database within 1 week of patient enrollment, and periodically checked for 
accuracy and completeness.   
 
F. Study Funding and Budget 
Clinical research can be expensive.  The hiring of research staff, use of 
equipment and study supplies can be costly, depending on nature of the 
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study.  A budget was created for this clinical trial (Appendix).  This budget 
included only the cost of equipment and supplies. The cost of hiring 
research personnel was not included as it was covered by our 
departmental funds.   
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Chapter 4. Preliminary Results 
A. Patient Accrual and Enrollment 
Over 800 patients were screened during the past 8 months.  As shown in 
Figure 3, a large proportion of the referrals were from the 
oxygen/nebulizer log, which was generated automatically every day.  
Referrals from thoracic medicine were most likely to be enrolled. 
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Figure 3. Referral Sources 
 
The study flow chart is shown in Figure 4.   Approximately 30% were 
discharged or died before we completed screening, reflecting the rapid 
pace of hospital discharge.  Among the 549 patients who completed 
screening, almost 90% were ineligible, with a diagnosis of curable cancer, 
not dyspneic enough, contraindications to BIPAP, delirium and non-cancer 
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dyspnea being the major reasons.   Among the 62 eligible patients who 
completed screening, 16 (26%) enrolled onto the study. 
 
Only 5 of 16 patients were able to complete both BIPAP and Vapotherm.  
As shown in Figure 3, 4 patients did not proceed to the second 
intervention after the full 1 hour washout period because they experienced 
prolonged relief of dyspnea and never returned to baseline (3 after BIPAP 
and 1 after Vapotherm).   Two patients who completed BIPAP as the first 
intervention dropout out during the washout period because of fatigue and 
pain requiring opioid use.  Three patients who tried BIPAP as the second 
intervention had to discontinue prematurely because they were unable to 
tolerate BIPAP (claustrophobia, positive pressure, and nausea after 45 
minutes of BIPAP).   Two other patients had difficulty tolerating both 
devices due to high levels of anxiety. 
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Figure 4. CONSORT Diagram 
 
 
B. Baseline Characteristics 
The baseline characteristics for the 16 patients enrolled onto this study so 
far are shown in Table 3.  Almost half of them had lung cancer, and a 
majority had metastatic disease.  Reasons for dyspnea included 
involvement of the lung parenchyma, pleural effusion, cachexia and 
lymphagitic carcinomatosis.  Pneumonia and pulmonary embolism were 
also present in a small proportion of patients.  Importantly, a substantial 
number of these patients were already on supplemental oxygen, 
bronchodilators, opioids and steroids. 
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Table 3. Patient Characteristics 
Clinical characteristics N (%)* 
Age, median (range) 62.5 (29-79) 
Female sex 9 (56%) 
Race 
 Caucasian 
 African American 
 
14 (87%) 
2 (13%) 
Cancer type 
 Lung 
 Breast 
 Gastrointestinal 
 Others 
 
7 (44%) 
4 (25%) 
2 (13%) 
3 (18%) 
Cancer stage 
 Metastatic 
 Locally advanced 
 
12 (75%) 
4 (25%) 
Co-morbidities 
 COPD 
 Asthma 
 CHF 
 Bronchiectasis 
 
4 (25%) 
0 
0 
0 
Performance Status 
 3 
 4 
 
13 (81%) 
3 (19%) 
Reasons for dyspnea** 
 Lung parenchymal involvement 
 Pleural effusion 
 Cachexia/muscle weakness 
 Lymphangitic carcinomatosis 
 Pneumonia 
 Pulmonary embolism 
 
12 (75%) 
6 (38%) 
6 (38%) 
2 (13%) 
3 (19%) 
1 (6%) 
Baseline medications 
 Supplemental oxygen 
 Bronchodilators 
 Opioids 
 Steroids 
 
16 (100%) 
16 (100%) 
15 (94%) 
8 (50%) 
Previous experience with BIPAP/Vapotherm 
 BIPAP 
 Vapotherm 
 
1 (6%) 
0 
 
C. Dyspnea Scores 
At baseline, the median dyspnea numeric rating scale was 7/10 
(interquartile range 5-8), and the median modified Borg scale was 4/10 (3-
7).  Using the Cancer Dyspnea Scale, our cohort reported a sense of effort 
subscale score of 11/20 (standard deviation (SD) 5), anxiety subscale 
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score of 7/16 (SD 5), discomfort subscale score of 6/12 (SD 3), and a total 
dyspnea score of 23/48 (SD 8). 
 
The changes in dyspnea score by numeric rating scale and modified Borg 
scale are shown in Figure 5.  Overall, BIPAP was associated with a 
median change in numeric rating score of -3 (N=10, interquartile range      
-6.3 to -1, p=0.007) and modified Borg score of -1 (N=10, interquartile 
range -3 to 0.3, p=0.058), while Vapotherm was associated with a median 
change in numeric rating score of -2 (N=9, interquartile range -3 to -1, 
p=0.011) and modified Borg score of -2.5 (N=8, interquartile range -5.5 to 
-0.1, p=0.051). 
 
Global assessment of dyspnea was consistent with the overall reduction of 
dyspnea scores, and confirmed that patient found the interventions helpful 
for their shortness of breath.  As shown in Figure 6, 10 of 11 patients who 
successfully completed BIPAP reported that it improved their dyspnea, 
with 4 of them experiencing at least a good deal of relief.  Seven of 9 
patients found Vapotherm to be useful in improving their dyspnea. 
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Figure 5. Changes in Dyspnea Scores.  The numeric rating scale was 
plotted for each patient before and after (A) BIPAP and (B) Vapotherm.   
The Borg scale was also plotted for each patient before and after (C) 
BIPAP and (D) Vapotherm. 
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Figure 6. Global Assessment of Dyspnea after BIPAP and Vapotherm  
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D. Physiologic Measures 
The physiologic changes before and after study interventions are shown in 
Table 4.  After BIPAP, patients generally had a lower heart rate, 
respiratory rate and oxygen saturation.  However, the transcutaneous 
carbon dioxide level did not change significantly.  Vapotherm was 
associated with improved oxygenation and decreased respiratory rate. 
 
Table 4. Physiologic Measures 
 
BIPAP Vapotherm 
Average values Before 
(SD) 
After  
(SD) 
Change 
(SD) 
P-value Before 
(SD) 
After  
(SD) 
Change 
(SD) 
P-value 
Heart rate (beats per 
minute) 
97  
(15) 
96 
(8) 
-6 
(5) 
0.01 107  
(17) 
105  
(14) 
-3  
(7) 
0.45 
Respiratory rate (per 
minute) 
26 
(5) 
22  
(5) 
-4  
(2) 
0.002 26 
(10) 
22 
(9) 
-4  
(10) 
0.32 
Systolic blood 
pressure (mmHg) 
128 
(20) 
128 
(14) 
-9  
(12) 
0.11 143 
(12) 
142 
(22) 
-2 
 (22) 
0.86 
Diastolic blood 
pressure (mmHg) 
74 
(10) 
75 
(17) 
0  
(10) 
0.94 84 
(5) 
85 
(9) 
+1  
(9) 
0.77 
Oxygen saturation 
(%) 
94 
(6) 
100 
(1) 
+8  
(5) 
0.006 92 
(4) 
97 
(1) 
+5  
(3) 
0.01 
Transcutaneous 
carbon dioxide level 
35  
(7) 
38 
(9) 
+2  
(3) 
0.13 36 
(4) 
33 
(5) 
-2  
(2) 
0.04 
Abbreviation: SD, standard deviation 
 
E. Adverse Effects 
As shown in Table 5, patients on BIPAP reported some difficulties drinking 
and talking as well as the mask being uncomfortable, which was balanced 
by less discomfort with nasal prong use.  Remarkably, patients reported a 
lesser sensation of suffocation on BIPAP.  The main adverse effect for 
Vapotherm was moisture in the nose. 
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No significant life-threatening adverse events were documented.  Four of 
16 patients died within 1 month of study completion.  The deaths were not 
attributed to this study, but reflected the poor prognosis of our patient 
population. 
 
Table 5. Patient Reported Adverse Effects Before and After 
BIPAP/Vapotherm  
 BIPAP Vapotherm 
Median Before 
(IQR) 
After  
(IQR) 
Change 
(IQR) P-value 
Before 
(IQR) 
After (IQR) Change 
(IQR) P-value 
Dry eyes 2  
(0-3.8) 
1.5  
(0, 4.5) 
0 
(0, 0) 
1.0 1  
(0, 3) 
0  
(0, 3) 
-1  
(-3, 0) 
0.07 
Eye irritation 0  
(0-1.8) 
0  
(0, 3) 
0 
(-0.75, 0) 
0.58 0  
(0, 5) 
0  
(0, 0) 
0  
(-3.5, 0) 
0.10 
Moist nose  2  
(0.5, 2.8) 
0  
(0, 2) 
0 
(-1.75, 0) 
0.75 2  
(0, 5) 
4.5  
(2.5, 6.3) 
+1.5  
(-0.3, 3.3) 
0.13 
Nasal prongs 
uncomfortable 
4.5  
(0.5, 5.8) 
0  
(0, 0) 
-2.5 
(-3.8,-1.2) 
0.007 0  
(0, 3) 
2  
(0, 2.5) 
0  
(-0.3,1.8) 
0.50 
Mask painful 0  
(0, 0) 
0.5  
(0, 3) 
+1.5 
(0.8, 2.3) 
0.07 - - - - 
Suffocating 3  
(0, 4.8) 
0  
(0, 0.8) 
-2.5 
(-3.8, 0) 
0.03 0  
(0, 7) 
0.5  
(0, 1.8) 
0  
(-0.3,0.3) 
0.71 
Bloating 0.5  
(0, 2.8) 
0  
(0, 1.8) 
0 
(-1, 0) 
0.59 3  
(1, 6) 
1  
(0, 2.3) 
-1  
(-1.8, 0) 
0.04 
Feel anxious 1.5  
(0, 2.0) 
0  
(0, 2.8) 
0 
(-0.8, 0) 
0.71 5  
(0, 6) 
0  
(0, 1) 
-2  
(-4.3, 0) 
0.07 
Trouble eating 4  
(0.5, 6) 
3.5  
(0.5, 6.5) 
-2 
(-2.8, 2) 
0.76 3  
(0, 6) 
1 
(0, 5.5) 
0  
(-0.3, 0.3) 
1.0 
Trouble drinking 2  
(0, 3) 
3.5 
(0, 7) 
0.5 
(-1.8, 4.5) 
0.44 0  
(0, 4) 
0  
(0, 0.5) 
0  
(0, 0) 
0.66 
Trouble talking 1.5  
(0, 4.3) 
6.5  
(2.8, 7.8) 
+2 
(0, 7) 
0.07 5  
(0, 6) 
1  
(0, 2.8) 
0  
(-1.8, 0.5) 
0.50 
Trouble 
sleeping 
2.5  
(0.3, 5.8) 
3.5  
(1.3, 5) 
0 
(-1, 2.3) 
0.67 7  
(5, 8) 
0  
(0, 1.3) 
-4.5  
(-7.3,-1.5) 
0.03 
Abbreviations: IQR, interquartile range; “-“, not applicable 
 
F. Washout Period 
The duration of washout period was an important outcome, as it is a 
measure of the duration of therapeutic effect after discontinuation of the 
first intervention.  Three of 6 patients who completed BIPAP and 1 of 7 
who completed Vapotherm as the first intervention experienced significant 
relief of dyspnea (i.e. ≤2/10) even after they returned to supplemental 
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oxygen for 1 hour, and were not eligible to proceed to the next phase of 
the study.    
 
Table 6. Washout Period Dyspnea Scores and Outcome 
   
Washout Period Numeric Rating Scores 
 
Patient 
# 
First 
treatment 
Baseline 
dyspnea 
0 
min 
10 
min 
20 
min 
30 
min 
40 
min 
50 
min 
60 
min 
Tried 2nd  
treatment 
4 BIPAP 7 6 2 1 2 2 2 3 Yes 
5 BIPAP 8 2 3 1 1 2 2 2 No 
6 BIPAP 5 2 5           Yes 
9 BIPAP 7 6 3 4 3       No* 
14 BIPAP 7 4 0 0 0 0 1 1 No 
15 BIPAP 5 2 2 2 2 2 2 2 No 
1 Vapotherm 8 8 - 7         Yes 
3 Vapotherm 6 3 3 5         Yes 
8 Vapotherm 5 3 3 4         Yes 
10 Vapotherm 8 5 7           Yes 
11 Vapotherm 10 4 2 1 1 4 2 2 No 
13 Vapotherm 3 2 3           Yes 
16 Vapotherm 9 6 7 7 6 7 6 6 Yes 
*This patient dropped out of study early during the washout period due to 
fatigue. 
 
G. Patient Preference and Satisfaction 
In addition to dyspnea scores and global assessments, patients who tried 
both interventions were asked at the end of the study to directly compare 
Vapotherm and BIPAP, and provide us with their overall preference.  
 
Among the 5 individuals who completed the entire study, 2 patients 
preferred Vapotherm for relief of dyspnea, 2 patients preferred BIPAP, and 
one liked both.  However, 4 of 5 patients reported BIPAP as causing more 
discomfort than Vapotherm.  Taking all factors into consideration, 2 
patients preferred Vapotherm, 2 patients preferred BIPAP, and 1 preferred 
both.   
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A satisfaction survey was completed by 10 patients who completed a 
substantial part of this study.  All 10 patients agreed that this was 
“worthwhile” and that they would “do this study again” and “recommend 
this study to others”.  Seven of 10 patients agreed that this study 
“improved his/her quality of life”.  
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Chapter 5. Discussion 
We presented the preliminary results of an open label randomized Phase 
II clinical trial comparing BIPAP and Vapotherm for the relief of persistent 
dyspnea among inpatients with advanced cancer.  After screening over 
800 patients, we found 62 (8%) eligible individuals, and enrolled 16 out of 
a planned total of 50 patients.  Despite challenges with recruitment and 
attrition, our results supported that both devices provide significant relief 
for dyspnea and decrease the work of breathing.   Further efforts to 
complete this study are warranted. 
 
A. Recruitment and Retention 
This study had several unique challenges, making it difficult to recruit 
patients.  First, our study population involved advanced cancer patients 
with persistent dyspnea, who represent a population with extremely poor 
prognosis and low performance status.  In fact, many of these patients 
were delirious, in acute distress, or too weak/tired to participate in our 
study.  Second, our study focused on recruiting patients with persistent 
rather than episodic dyspnea because we believed that BIPAP and 
Vapotherm are best suited for this purpose.  This significantly limits the 
number of eligible subjects as persistent dyspnea is not as common (46).  
Third, only hospitalized patients were included in this study.  These 
patients were generally admitted for acute illness or complications, with 
rapid changes in their health status.  This, coupled with the busy hospital 
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course with multiple investigations and/or procedures, and the 
unpredictable discharge planning, made it difficult to find a window of 
opportunity for patients to participate in the study.  Finally, patients were 
generally less inclined to enroll onto supportive care studies than cancer 
treatment trials (47). Thus, successful recruitment required screening of 
large number of patients, regular monitoring, impeccable coordination, 
cohesive teamwork and a flexible schedule.  It was encouraging that we 
were able to enroll 16 patients between October 2009 and March 2010, 
representing approximately one third of the accrual target.  Putting this in 
perspective, a review of the 6 randomized clinical trials included in a 
recent metaanalysis examining the effect of oxygen for dyspnea showed 
the median sample size to be 24 (range 7-51) (3). 
 
Despite the relatively short duration of this study, attrition represented 
another major challenge.  Only 5 of 16 subjects were able to complete the 
entire study.  Four subjects did not proceed to the second phase because 
their dyspnea score were too low after the first intervention.  Five subjects 
had some difficulty tolerating BIPAP due to anxiety, claustrophobia, 
positive airway pressure and nausea.  Our finding is consistent with 
literature which showed that 10-30% of patients have BIPAP intolerance 
(48, 49).  Interestingly, 2 of these patients had difficulty tolerating 
Vapotherm as well.  Thus, BIPAP and Vapotherm may not be appropriate 
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for all patients, particularly those who are frail and in distress.  Better 
patient selection and longer washout period are necessary for future trials.   
 
B. Improvement in Dyspnea 
The numeric rating scale and modified Borg scale indicated some 
improvement with both BIPAP and Vapotherm.  Due to the small sample 
size, we did not compare the change in dyspnea scores between the two 
interventions.  However, the numeric rating scale appeared to favor 
BIPAP, while the modified Borg scale showed greater improvement with 
Vapotherm.  This discrepancy may be due to random variation, the 
different sensitivity of the scales, and/or how patients interpreted these 
tools.  A larger sample size with formal statistical testing is necessary. 
 
A difference of 21 mm on a 100 mm visual analog scale was found to be 
clinically significant in a study of heart failure patients (50).  However, 
there is no established minimal clinical important difference for both 
numeric rating scale and modified Borg scale (37).  Thus, we included a 
global symptom assessment at the end of each intervention.  Consistent 
with the dyspnea scores, a majority of the patients reported the devices to 
be useful in relieving their dyspnea.  This benefit, if confirmed, is highly 
encouraging given that a majority of our patients were already on maximal 
supportive measures with supplemental oxygen, steroids, opioids and 
bronchodilators.  As hypothesized, BIPAP and Vapotherm may exert their 
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therapeutic effects on dyspnea through multiple mechanisms rather than 
just improved oxygenation alone. 
 
We were somewhat surprised by the prolonged washout period, as other 
studies demonstrated that patients become dyspneic shortly after 
discontinuation of supplemental oxygen (10, 31).  Three patients who tried 
BIPAP and one on Vapotherm reported significant and long lasting 
improvement after discontinuation of the respective interventions.  We 
initially hypothesized that BIPAP is better than Vapotherm for relief of 
dyspnea, given that it not only improves oxygenation, but also ventilation, 
muscle fatigue and alveolar recruitment.  Upon completion of accrual, we 
would be testing this specific hypothesis. 
 
C. Toxicities 
Safety is an important outcome for this study.  Patients who were able to 
tolerate the devices reported minimal toxicities.  While the BIPAP mask 
was associated with some discomfort, patients also found the nasal 
prongs to be somewhat uncomfortable.  Although BIPAP may result in the 
sensation of suffocation in some patients, our patients reported a 
reduction in this symptom while on BIPAP, consistent with its beneficial 
effort on dyspnea. 
 
D. Improvement in Physiologic Measures 
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Our preliminary examination of physiologic measures demonstrated that 
the oxygen saturation improved while the respiratory rate decreased by 
approximately 4/minute with both interventions, consistent with a 
decreased work of breathing.  Interestingly, tissue carbon dioxide level did 
not drop significantly with BIPAP.  However, it is important to point out that 
a majority of the patients enrolled so far had hypoxemic respiratory failure 
rather than hypercapneic respiratory failure.  As shown by the 
transcutaneous carbon dioxide level, these patients were in a 
hyperventilation state at baseline, and thus BIPAP had limited impact on 
this parameter. 
 
E. Limitations 
This study has several limitations.  First, the primary outcome measure of 
dyspnea was a subjective numeric rating scale.  Rather than a direct 
benefit from the study interventions, the positive finding could simply be 
the result of placebo and/or trial effect, such as positive interaction with 
study staff.  To assess dyspnea from different angles, we incorporated two 
different dyspnea scales, global assessment, washout period assessment 
and a number of objective secondary endpoints such as vital signs.  
Second, ascertainment bias was particularly important as blinding was not 
possible for this study.  Third, we only examined the study interventions 
for 2 hours each and in hospitalized patients only.  The longer term benefit 
in outpatients is unclear. Further studies are necessary to examine these 
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options.  Finally, it is important to recognize the interim results reported 
here were based on 16 patients only, and our conclusions could change 
with a larger sample size. 
 
F. Conclusions 
Based on the preliminary analysis of 16 patients, we found that BIPAP and 
Vapotherm provided excellent dyspnea relief for advanced cancer patients 
who had persistent dyspnea despite standard therapeutic options.  The 
use of these devices was associated with minimal toxicities and positive 
physiologic changes.  We were also able to demonstrate the feasibility of 
enrolling very sick patients onto this study.  Our next step would be to 
complete this clinical trial, which would allow us to directly compare the 
efficacy of these two modalities.  If the findings remained positive, larger, 
more definitive research studies examining these interventions for longer 
periods are warranted.   
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Appendix 
A. Study Forms 
 
 
Patient Demographics and Baseline Characteristics for Dyspnea Study 
Assessment #1 Only 
 
Age:______________ Gender:___________ Date of Birth:___________ 
Ethnicity: 
  White 
  Asian 
 Black 
 Hispanic 
 Other____________ 
Cancer Diagnosis: 
 Date of diagnosis: 
 Cancer histology: 
 Cancer stage: 
 Cancer treatments received 
(include  systemic therapy and 
radiation): 
 
____________________________ 
____________________________ 
____________________________ 
 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
 
Medical Co-morbidities: 
 COPD 
 Asthma 
 CHF 
 Bronchiectasis 
 Others 
 
 
 Yes    No  
 Yes    No  
 Yes    No  
 Yes    No  
____________________________ 
____________________________ 
____________________________ 
 
Reason for dyspnea: ____________________________ 
 
Current Medications: 
 Bronchodilators (e.g. 
Salbutamol): 
  
 Steroids (e.g. prednisone): 
  
 Opioids (e.g. morphine): 
  
 Others 
 
Please list name, dosage, frequency and 
route 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Previous BIPAP/CPAP/Vapotherm 
 BIPAP 
 
 
 
 CPAP 
 
 
 
 Vapotherm 
 
 
 
 
If yes,  How many times in the past? _____ 
 When was the last time? _____ 
 What was reason? _____ 
    
If yes,  How many times in the past? _____ 
 When was the last time? _____ 
 What was reason? _____ 
 
If yes,  How many times in the past? _____ 
 When was the last time? _____ 
 What was reason? _____ 
 
Current ECOG Performance Status:  
  1 
  2 
 
  
 3 
 4 
 
Physical Examination Findings: 
 Weight (kg) 
 Heart rate (beats/minute) 
 Respiratory rate (/minute) 
 Blood pressure 
(systolic/diastolic) 
 Temperature (°F) 
 Oxygen saturation (%) 
 Supplemental oxygen (L/min) 
 Respiratory examination 
 Cardiac examination 
 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
____________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Numeric Rating Scale for Screening Purposes (2 Step Consent) 
 
 
Please circle the number to indicate the average level of your shortness of breath over 
the last 2 weeks. 
 
No shortness Worst  
of breath possible  
 shortness 
 of breath 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
Please circle the number to indicate the level of your shortness of breath NOW. 
 
No shortness Worst  
of breath possible  
 shortness 
 of breath 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
 
 
 
 
Research Staff Only 
 
Patient agreed to be screened:  Yes  No  
 
 If patient disagreed, please ___________________________ 
 indicate reason(s): ___________________________ 
   ___________________________ 
    
 
After screening, patient is eligible:  Yes  No  
 
 If not eligible, please ___________________________ 
 indicate reason(s): ___________________________ 
   ___________________________ 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Numeric Rating Scale for Study Assessments 
Assessment #1, #2, #3, #4 (please circle) 
 
Please circle the number to indicate the level of your shortness of breath NOW. 
 
No shortness Worst  
of breath possible  
 shortness 
 of breath 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Modified Borg Scale for Study Assessments 
Assessment #1, #2, #3, #4 (please circle) 
 
Please circle the number that best describes the sensation of your shortness of 
breath NOW (e.g. extremely weak sensation, extremely strong sensation). 
 
0 Nothing at all 
0.5 Extremely weak (just noticeable) 
1 Very weak 
2 Weak (light) 
3 Moderate 
4 Somewhat strong 
5 Strong (heavy) 
6  
7 Very strong 
8  
9  
10 Extremely strong (almost maximal) 
* Maximal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
 
  56 
 
Cancer Dyspnoea Scale 
Assessment #1 only 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Global Symptom Evaluation 
Assessments #2 only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Global Symptom Evaluation and Study Satisfaction 
Assessment #4 only 
 
 
 
 
 
 
 
 
 
Research Staff Signature: 
________________ 
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Patient Preference Survey 
Assessment #4 only 
 
1. How would you consider your breathing 
while on BIPAP as compared to before the 
study?  (Choose one)  
    Much worse  
    Worse 
    Same 
    Better 
    Much better 
 
2. How would you consider your breathing 
while on VapoTherm as compared to before 
the study?  (Choose one) 
    Much worse  
    Worse 
    Same 
    Better 
    Much better 
 
3. How would you consider your breathing 
comparing BIPAP to VapoTherm?  (Choose 
one) 
    BIPAP is much better 
    BIPAP is better  
    Same 
    VapoTherm is better 
    VapoTherm is much better 
 
4. Which of the following would you prefer 
the most for relief of your shortness of 
breath? (Choose one)  
    BIPAP 
    VapoTherm 
    Both 
    None of above 
 
5. Which of the following causes you the 
most discomfort?  (Choose one)  
    BIPAP 
    VapoTherm 
    Both 
    None of above 
 
6. Which of the following would you prefer 
the most overall, taking all factors into 
consideration?  (Choose one)  
    BIPAP 
    VapoTherm 
    Both 
  None of above 
 
7. If you have tried both nasal and facial 
mask while on BIPAP, which one do you 
prefer more?  (Choose one)  
    Facial mask 
    Nasal mask 
    Both 
    None of above 
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Research Staff Signature: ________________ 
 
Washout Period Data Collection and Decision Making Sheet 
 During washout period only 
 
Baseline dyspnea score (assessment #1) 
  
_____/10 
Cutoff score for starting 2nd intervention (if baseline dyspnea score = 3, then the 
cutoff score = 3; otherwise, subtract 1 from the baseline dyspnea score to get 
cutoff score) 
 
_____/10 
 
 
Please indicate patients’ level of dyspnea during the washout period: 
Time 
(24:00) 
Interval Dyspnea score Instruction 
 10 minute _____/10 Proceed to 2nd intervention if ≥cutoff; otherwise, 
wait 10 minutes and repeat assessment 
 
 20 minute _____/10 Proceed to 2nd intervention if ≥cutoff; otherwise, 
wait 10 minutes and repeat assessment 
 
 30 minute _____/10 Proceed to 2nd intervention if ≥cutoff; otherwise, 
wait 10 minutes and repeat assessment 
 
 40 minute _____/10 Proceed to 2nd intervention if ≥cutoff; otherwise, 
wait 10 minutes and repeat assessment 
 
 50 minute _____/10 Proceed to 2nd intervention if ≥cutoff; otherwise, 
wait 10 minutes and repeat assessment 
 
 60 minute _____/10 Proceed to 2nd intervention if ≥cutoff OR if score 
≥3/10; otherwise, terminate study 
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Research Staff Signature: ________________ 
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Patient Reported Adverse Effect Form 
 Assessment #1, #2, #3, #4 (please circle) 
 
 
Please indicate if you experience any of the following now: 
    
   Worst 
 Not at all possible 
 
I have dry eyes    0 1 2 3 4 5 6 7 8 9 10 
 
I have eye irritation   0 1 2 3 4 5 6 7 8 9 10 
 
Moisture in my nose   0 1 2 3 4 5 6 7 8 9 10 
 
The nasal prong is   0 1 2 3 4 5 6 7 8 9 10 
uncomfortable 
 
The mask is painful   0 1 2 3 4 5 6 7 8 9 10 
 
I feel I am suffocating   0 1 2 3 4 5 6 7 8 9 10 
 
My stomach is bloated   0 1 2 3 4 5 6 7 8 9 10 
 
I feel anxious    0 1 2 3 4 5 6 7 8 9 10 
 
I have trouble eating    0 1 2 3 4 5 6 7 8 9 10 
 
I have trouble drinking   0 1 2 3 4 5 6 7 8 9 10 
 
I have trouble talking    0 1 2 3 4 5 6 7 8 9 10 
 
I have trouble sleeping   0 1 2 3 4 5 6 7 8 9 10 
 
Others    0 1 2 3 4 5 6 7 8 9 10 
Please specify:_____________ 
 
Others    0 1 2 3 4 5 6 7 8 9 10 
Please specify:_____________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: ________________ 
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Dropout 
Assessment #2, #3, #4 (please circle) 
 
Dropout (only if patient unable to complete study) 
Time of study dropout 
 
Phase of study dropout 
 
 
 
 
 
Reason(s) for dropout 
 
_____________________ 
 
 Before starting intervention 1 
 During intervention 1 
 During washout period 
 During intervention 2 
 After intervention 2 
 
_____________________ 
_____________________ 
_____________________ 
_____________________ 
_____________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Staff Signature: ________________ 
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Data Collection for Respiratory Settings 
 
 Assessment 
#1 
Assessment #2 
30/60/90/120min 
Assessment 
#3 
Assessment #4 
30/60/90/120min 
Start time 
 
    
End time 
 
    
Device (Bipap, 
Vapotherm or 
Suppl. 02) 
    
Interface (facial 
mask, nasal mask, 
nasal prongs) 
    
Fi02 (%) 
Reading 
    
IPAP (mmHg) 
Reading 
    
EPAP (mmHg) 
Reading 
    
O2 flow (Vapotherm 
or Supplemental 
O2) Reading 
    
TcC02 (mmHg) 
Q30min 
          
Sp02 (%) 
Q30min 
          
RR (minute) 
 
          
HR (minute) 
 
          
BP (systolic/ 
diastolic) 
 
          
Temp (ºF) 
 
    
Comments  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Research Staff Signature: __________________________ 
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B. Study Consent 
 
INFORMED CONSENT/AUTHORIZATION FOR 
PARTICIPATION IN RESEARCH 
 
An Exploratory Trial of Bilevel Positive Airway Pressure Device 
and High Flow Oxygen for Persistent Dyspnea in Advanced 
Cancer Patients 
2009-0164 
 
 
Study Chair: Eduardo Bruera 
 
 
1
. 
    
 Participant’s Name  Medical Record Number 
 
 
 
You are being asked to take part in this clinical research study at The 
University of Texas M. D. Anderson Cancer Center ("M. D. Anderson").  
This consent form explains why this research study is being done and 
what your role will be if you choose to take part. This form also 
describes the possible risks connected with being in this study.  After 
reviewing this information with the person responsible for your 
enrollment, you should know enough to be able to make an informed 
decision on whether you want to take part in the study. 
 
You are being asked to take part in this study because you have 
advanced cancer and are experiencing shortness of breath. 
 
 
DESCRIPTION OF RESEARCH 
 
 
2. PURPOSE OF STUDY 
 
The goal of this clinical research study is to learn if specialized 
breathing devices reduce the sensation of shortness of breath in 
patients with advanced cancer who are experiencing shortness of 
breath.  Researchers want to learn if these devices can help to 
control shortness of breath. 
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The 2 devices being tested and compared are called BiPAP (bilevel 
positive airway pressure) and Vapotherm. 
 
 
3. DESCRIPTION OF STUDY 
 
Study Devices 
The BiPAP device is designed to help people get more air in and out 
of their lungs without using as much effort as regular breathing.  The 
air is given through a mask, and the amount of air can be set to 
different levels. 
 
The Vapotherm device is also designed to deliver air in and out of the 
lungs.  The air is warmed, filtered for bacteria, and then delivered 
through the nose using a tube under the nostrils. 
 
Screening Tests 
Signing this consent form does not mean that you will be able to take 
part in this study.  You will have "screening tests” to help the doctor 
decide if you are eligible to take part in this study.  The following tests 
and procedures will be performed: 
You will have a physical exam, including measurement of your 
weight and vital signs (heart rate, breathing rate, blood 
pressure, and temperature). 
The level of oxygen in your blood will be measured using a soft 
clamp placed on  your finger. 
You will be asked about your breathing, and you will rate how 
hard it is to breathe. 
You will complete 3 questionnaires.  Two (2) of them have 
questions about the breathing symptoms, and the third 
questionnaire has questions about any confusion you may be 
experiencing.  This should take a total of less than 15 minutes. 
From your medical record, the study staff will collect information 
about your age, sex, race, cancer type, any drugs you are 
taking, and possible causes of shortness of breath. 
 
The research staff will discuss the screening test results with you.  If 
the screening tests show that you are not eligible to take part in the 
study, you will not be enrolled.  Other treatment options will be 
discussed with you. 
 
Study Groups 
If you are found to be eligible to take part in this study, you will be 
randomly assigned (as in the flip of a coin) to 1 of 2 groups. 
Group 1 will receive air through BiPAP for up to 2 hours and 
then air through Vapotherm for up to 2 hours. 
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Group 2 will receive air through Vapotherm for up to 2 hours 
and then air through BiPAP for up to 2 hours.  
 
The study staff will help you use the devices. 
 
If you have trouble with one of the devices, you can be switched to the 
other device before the 2-hour period is over. 
 
After using the first device, you will wait for up to 60 minutes before 
switching over to the other device.  This waiting period will occur no 
matter if you used the first device for the full 2 hours or not. 
 
During the waiting period, you will return to the same air delivery 
device and oxygen level that you were using just before you started the 
study.  The study staff will also be checking to see if you are still 
eligible to use the second device. 
 
Study Tests 
During the study period, your vital signs and level of air breathed out 
will be recorded using a measuring device on your chest. 
 
Before and after using the devices, you will rate how hard it is to catch 
your breath. 
 
After using the second device, you will fill out a questionnaire that has 
questions about which device you prefer.  This should take less than 5 
minutes. 
 
Length of Study 
You will be on this study for up to 5 hours.  You will be taken off study 
and the device will be stopped if intolerable side effects occur while 
using a study device. 
 
Use of Other Drugs 
During the 4-5 hour study period, you will not be allowed to take certain 
drugs for standard care that may affect the study tests.  These drugs 
include certain pain-killer drugs (such as morphine and 
hydromorphone), steroids (such as prednisone and dexamethasone), 
and inhaled drugs (such as ipratropium and salbutamol). 
 
Any doses of inhaled drugs (regularly scheduled doses and "as 
needed" doses) and any "as needed" doses of pain-killer drugs and 
steroids that fall within the 4-5 hour study period will be put on hold and 
will be given to you right after the study is complete. 
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You may, however, choose to take these drugs, either because your 
shortness of breath is not controlled, or because these drugs are 
needed to treat other problems (such as pain).  If you and your doctor 
decide that you should take these drugs during the study period, you 
will be taken off study so you can receive these drugs.  The reason for 
stopping your study participation is that these drugs may affect how 
you rate your shortness of breath. 
 
This is an investigational study.  The BIPAP and Vapotherm devices 
are commercially available and FDA approved for delivering oxygen 
when medically needed, including in patients with advanced cancer. 
The investigational part of this study is to collect information from 
asking patients to rate how well the study devices may affect shortness 
of breath. 
 
There will be no cost to you for using the breathing devices during the 
study. 
 
Up to 50 patients will be enrolled in this study. All will be enrolled at M. 
D. Anderson. 
 
 
4. RISKS, SIDE EFFECTS, AND DISCOMFORTS TO PARTICIPANTS 
 
While on this study, you are at risk for side effects.  You should discuss 
these with the study doctor.  The known side effects are listed in this 
form, but they will vary from person to person.  In most cases, the side 
effects will go away shortly after the device is stopped but in some 
cases the side effects may last longer.   
 
"Likely" side effects occur in more than 20% of patients, "common" 
side effects occur in 3-20% of patients, and "rare" side effects occur in 
fewer than 3% of patients. 
 
BiPAP Side Effects 
 
The BiPAP face mask may likely cause discomfort. 
 
BiPAP may commonly cause stomach bloating and/or drying of the 
eyes.   
 
BiPAP may rarely cause pink eye. 
 
Vapotherm Side Effects 
 
Vapotherm may likely cause uncomfortable moisture in the nose. 
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Vapotherm may rarely cause the feeling of breathing difficulty (like you 
are choking or suffocating but are actually not). 
 
Other Risks 
 
Questionnaires may contain questions that are sensitive in nature.  
You may refuse to answer any question that makes you feel 
uncomfortable.  If you have concerns after completing the 
questionnaire, you are encouraged to contact your doctor or the study 
chair. 
 
This study may involve unpredictable risks to the participants. 
 
 
 
5. POTENTIAL BENEFITS 
 
The breathing devices may help to control the shortness of breath 
during the 4-5 hour study period.  Future patients may benefit from 
what is learned in this study.  There may be no benefits for you in 
this study. 
 
 
6. ALTERNATE PROCEDURES OR TREATMENTS 
 
You may choose not to take part in this study.  You may choose to 
receive drugs for shortness of breath.  The drugs may include, for 
example, opioids (pain-relievers) or bronchodilators (airway-wideners).  
You may use either BiPAP or Vapotherm without taking part in this 
study. 
 
You may choose to receive other investigational therapy, if available.  
You may choose not to have treatment for shortness of breath at all.  
In all cases, you will receive appropriate medical care. 
 
I understand that the following statements about this study are 
true: 
 
7. M. D. Anderson may benefit financially from my participation and/or 
from what is learned in this study. 
 
8. I may ask the study chair any questions I have about this study, 
including questions about the costs.  I may contact the study chair, Dr. 
Eduardo Bruera, at 713-792-6085.  I may also contact the Chair of M. 
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D. Anderson's IRB at 713-792-2933 with any questions that have to 
do with this study or my rights as a study participant. 
 
9. My participation in this research study is strictly voluntary.  I may 
refuse to take part in this study without any penalty or loss of benefits 
to which I am otherwise entitled.  I may also withdraw from 
participation in this study at any time without any penalty or loss of 
benefits.  I should first discuss leaving the study with my doctor.  If I 
withdraw from this study, I may still be treated at M. D. Anderson. 
 
10. I understand that the study may be changed or stopped at any time by 
the study chair, the U.S. Food and Drug Administration (FDA), the 
Office for Human Research Protections (OHRP) (a regulatory agency 
that oversees research in humans), or the IRB of M. D. Anderson. 
 
11. I will be informed of any new findings that might affect my willingness 
to continue taking part in the study. 
 
12. M. D. Anderson will take appropriate steps to keep my personal health 
information private.  However, there is no guarantee of absolute 
privacy.  Federal agencies (such as the FDA and the OHRP), and the 
IRB of M. D. Anderson might review my record to collect data or to 
check that the research is being done safely and correctly.  In some 
situations, the FDA could be required to reveal the names of 
participants. 
 
13. If I suffer injury as a direct result of taking part in this study, M. D. 
Anderson will provide medical care.  However, this medical care will 
be billed to my insurance provider or me in the ordinary manner.  I 
understand that I will not be reimbursed for expenses or compensated 
financially by M. D. Anderson for this injury.  I may also contact the 
Chair of M. D. Anderson’s IRB at 713-792-2933 with questions about 
study-related injuries. 
 
14. Certain tests, procedures, and/or medications that I may receive as 
part of this study may be without cost to me because they are for 
research purposes only.  However, my insurance provider or I may be 
financially responsible for the cost of supportive care and treatment of 
any complications resulting from the research tests, procedures, 
and/or medications, including hospitalization, nausea, vomiting, low 
blood cell counts, and dehydration.  Standard medical care that I 
receive under this research study will be billed to my insurance 
provider and/or me in the ordinary manner.  I should learn before 
taking part in this study which parts of the research-related care will 
be provided without charge, which costs my insurance provider will 
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pay for, and which costs will be my responsibility.  I may ask to speak 
with a financial counselor about the costs of this study. 
 
15. I understand that there are no plans to compensate me for any 
patents or discoveries that may result from my participation in this 
research.  I will receive no compensation for taking part in this study. 
 
Authorization for Use and Disclosure of Protected Health 
Information: 
 
A. During the course of this study, the research team at M. D. Anderson 
will be collecting information about you.  This information may include 
your medical history, study schedule, and the results of any of your 
tests, therapies, and/or procedures.  The purpose of collecting and 
sharing this information is to learn about how the study procedures 
may affect the disease and any study-related side effects. Your doctor 
and the research team may share your study information with the 
parties named in Section E below.   
 
B. If you refuse to provide your authorization to disclose your protected 
health information, you will not be able to participate in this research 
study. 
 
C. Your protected health information will be protected according to state 
and federal law.  However, there is no guarantee that your information 
will remain confidential, and it may be re-disclosed at some point. 
 
D. All identifying information such as your name and address will be kept 
private. This information may be kept at M. D. Anderson forever.  You 
will be assigned a code number so that your name will not be used. 
The research team at M. D. Anderson will be able to link the code 
number to your name.  In some instances, in order to ensure the 
scientific value of the study, the parties named in Section E below will 
be able to view your study record but will not be permitted to copy any 
identifying information contained in your record. 
 
E. Your information may be shared with the following parties:  
 
The FDA 
The OHRP  
The IRB of M. D. Anderson 
Officials of M. D. Anderson 
Clinical study monitors who verify the accuracy of the 
information 
Individuals with medical backgrounds who determine the effect 
that the study procedures may have on the disease 
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Individuals who put all the study information together in report 
form 
 
F. You have the right to see and reproduce your records related to the 
research study, and ask for corrections, for as long as this information 
is held by the study chair and/or M. D. Anderson.  However, in some 
studies, in order to ensure the scientific value of the study, 
participants are not able to view or reproduce their study records until 
the research has been completed with all participants in the study.  If 
possible for this study, your doctor will be able to discuss your clinical 
test results with you. 
 
G. There is no expiration date for the use of your protected health 
information.  You may withdraw your authorization to share your 
protected health information at any time in writing.  Instructions on 
how to do this can be found in the M. D. Anderson Notice of Privacy 
Practices (NPP).  You may contact the IRB Staff at 713-792-2933 with 
questions about how to find the NPP.  If you withdraw your 
authorization, you will be removed from the study and the study chair 
and staff will no longer use or disclose your protected health 
information in connection with this study, unless the study chair or 
staff needs to use or disclose some of your research-related protected 
health information to preserve the scientific value of the study.  The 
parties listed in Section E above may use any study data that were 
collected before you canceled your authorization. 
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CONSENT/PERMISSION/AUTHORIZATION FOR TREATMENT 
 
Having read and understood the above and having had the chance to ask 
questions about this study, think about the study, and talk with others as 
needed, I give the study chair permission to enroll me on this study.  By 
signing this consent form, I am not giving up any of my legal rights.  I have 
been given a signed copy of this consent document. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF PARTICIPANT  
DATE 
 
 
I was present during the explanation of the research to be performed 
under Protocol 2009-0164. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF WITNESS TO THE VERBAL CONSENT 
PRESENTATION (OTHER THAN PHYSICIAN OR STUDY CHAIR) 
 
DATE 
 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF PERSON  RESPONSIBLE & RELATIONSHIP  
DATE 
 
 
 
I have discussed this clinical research study with the participant and/or his 
or her authorized representative, using language that is understandable 
and appropriate.  I believe that I have fully informed this participant of the 
nature of this study and its possible benefits and risks and that the 
participant understood this explanation. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF STUDY CHAIR OR PERSON OBTAINING 
CONSENT 
 
DATE 
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Translator 
 
I have translated the above informed consent as written (without additions or 
subtractions)  
into _____________________________ and assisted the people 
obtaining/providing 
 (Name of Language) 
consent by translating all questions and responses during the consent 
process for this participant. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
 
NAME OF TRANSLATOR 
  
SIGNATURE OF TRANSLATOR 
 
DATE 
 
 
 
 Please check here if the translator was a member of the research 
team.  (If checked, a witness, other than the translator, must sign the 
witness line.) 
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C. Standard Operating Procedure 
 
 
 
 
 
 
 
Standard Operating Procedure for  
 
 
Vapotherm and Intermittent BiPap for Respiratory 
Support in Patients with Advanced Neoplasm Trial 
[VIBRANT Study] 
 
Protocol 2009-0164 
 
 
 
 
 
 
Table of Contents 
 
STUDY CONTACTS ................................................................................................................................. 76 
GENERAL INFORMATION AND STUDY FLOWCHART ................................................................ 77 
ELIGIBILITY CRITERIA........................................................................................................................ 79 
1) PRE-SCREENING ........................................................................................................................... 80 
2) SCREENING..................................................................................................................................... 81 
3) ASSESSMENT #1 ............................................................................................................................. 82 
4) INTERVENTION #1 ........................................................................................................................ 83 
5) ASSESSMENT #2 ............................................................................................................................. 84 
6) WASHOUT PERIOD AND ASSESSMENT #3 ............................................................................. 85 
7) INTERVENTION #2 ........................................................................................................................ 86 
8) ASSESSMENT #4 ............................................................................................................................. 87 
 
 76 
PRINCIPAL INVESTIGATOR: DR. EDUARDO BRUERA 
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General Information and Study Flowchart 
• Study runs Monday to Friday, 8am-5pm 
• Study interventions need to be initiated at or before noon 
• Any questions during this study should be directed to Dr. David Hui (606-
3376, dhui@mdanderson.org) 
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Eligibility Criteria 
Inclusion criteria: 
1) Diagnosis of advanced cancer, defined as locally advanced, recurrent or 
metastatic disease 
2) Patients with persistent dyspnea, defined in this study as dyspnea at rest with 
an average intensity level ≥3 out of a numeric rating scale from 0 to 10 for at 
least 2 week and just prior to study initiation, despite supplemental oxygen of 
up to 21 L/min to keep oxygen saturation ≥90% 
3) Dyspnea is judged clinically to be predominantly due to underlying 
malignancy, with or without obstructive lung disease 
4) Inpatient at M.D. Anderson Cancer Center 
5) On stable doses of opioids, steroids and bronchodilators, defined as no 
significant change (±20%) in the total daily dose over the last 48 hours 
6) Able to communicate in English 
7) Expected life expectancy >1 week 
8) Patients with a diagnosis of pneumonia are also eligible for this study if they 
meet the eligibility criteria above, with dyspnea ≥2 weeks prior to the 
diagnosis of pneumonia. 
 
Exclusion criteria: 
1) Patients who remain hypoxic (i.e. O2 saturation <90% despite maximal 
oxygen delivery (21 L/min) are not included in this study because they are 
considered to have severe life-threatening respiratory failure and are too 
unstable for study inclusion. 
2) Hemodynamic instability (HR >140, SBP <80) within 24 hours of study 
initiation as per clinic station 
3) Acute respiratory distress requiring intubation 
4) Delirium as indicated by a Memorial Delirium Assessment Scale (MDAS) of 
13 or higher 
5) Glasglow coma scale <8 
6) Excessive airway secretions interfering with BIPAP administration 
7) History of facial trauma within 1 month of enrollment 
8) Upper GI bleed within 2 weeks or esophageal rupture of enrollment 
9) Partial or complete small bowel obstruction or severe nausea/vomiting (ESAS 
nausea >7/10) within 48 hours of enrollment 
10) Hemoglobin <8 g/dL at the time of enrollment (blood draw within last 2 weeks) 
11) Acute exacerbation of COPD or CHF within 2 weeks of enrollment by history 
or physical 
12) Pulmonary embolus within 1 week of enrollment by history or physical 
13) Unwilling to provide informed consent 
14) Age 18 or under 
15) Diagnosis of non-cancer related dyspnea (e.g. COPD, CHF or any chronic 
respiratory disease) requiring supplemental home oxygen prior to 
hospitalization. 
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1) Pre-screening (Clinical RT/Research MD) 
a) Clinical RTs (names and contact) in AM shift identifies potentially eligible 
inpatients for dyspnea study: 
i) Advanced cancer (metastatic or locally advanced) 
ii) On supplemental oxygen and sat >90% 
iii) Hemodynamically stable 
iv) Likely able to tolerate BIPAP and Vapotherm 
v) Alert and oriented 
vi) “Do you have shortness of breath?  If yes, for how long roughly?”  If 
the answer is for 2 weeks or longer, patients are potentially eligible for 
study 
b) If patient met above criteria, please discuss the following with the patient: 
i) “We have a clinical trial to see if we can help improve your shortness of 
breath.  You get to try two different types of breathing machines for 
about 2 hours each.  I think it may be of interest to you.  Would you like 
to learn more about this study?” 
ii) If yes, this patient is potentially eligible 
c) Try to identify at least one potentially eligible patient per day per RT. 
d) Clinical RTs page research MD on or before 10am, regardless of whether 
you have a patient or not 
i) If potentially eligible patient, provide the MRN, name and location for 
any potentially eligible patients.  This will be captured on a screening 
log 
ii) If no patients, please let research MD know as well 
e) If research MD has not received any pages by 10am, will page the 
research RTs to find out what happened. 
f) If research MD not answering within 10 minutes, please page research 
MD again.  If still no answer within 5 minutes, page second research MD. 
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2) Screening (Research MD/RN, estimate ~1 hour) 
a) Research MD will review patient data (starting with the most likely 
candidate) on Clinic Station to determine eligibility.  If patient not 
eligible on paper, research RN will inform patients. 
b) If likely eligible, research MD will inform research RN do further pre-
screening on Clinic Station before going up to unit to approach patient 
to  
i) Discuss study protocol briefly, and ask for permission to screen 
ii) Ask him/her about dyspnea rating over the last 2 weeks on 
numeric rating scale (has to be ≥3/10) 
iii) Ask him/her about dyspnea rating now on numeric rating scale 
(has to be ≥3/10) 
iv) Document the above in Appendix B 
c) Research RN will complete rest of eligibility screening 
i) If eligible, explain study in detail, provide consent form and ask if 
patient agrees to participate.   If yes, go to Section 2.c.iv.  If no, go 
to Section 2.c.i 
ii) If not eligible or patient refused to participate, thank the patient and 
inform RT patient not enrolled 
iii) Document the above in Appendix B 
iv) Ensure patient signed consent form 
d) Determine if study can be started today 
i) Research RN will check with patient first 
ii) Research RN will notify the unit RN most responsible for the 
patient’s care at the time that patient has agreed to participate in 
this 5 hour study, and discuss the following: 
(1) Whether there are any tests/procedures (if yes, whether they 
can be rescheduled until after the study?) 
(2) Patients who are already on scheduled opioids or steroids may 
continue to receive them as per clinical care 
(3) Patients who require any breakthrough opioids (parenteral, 
oral, inhaled), breakthrough steroids (parenteral, oral or 
inhaled) or scheduled/breakthrough bronchodilators will be 
asked to hold the medications if possible.  Otherwise, they will 
need to come off study 
iii) If patient okay and available, notify research MD so he will notify 
attending physician of the study and obtain approval. 
iv) Once all parties have agreed to proceed (patient, attending MD, 
unit RN, research RN/MD), then proceed to Section 3   
v) If not, determine if alternative time/day would work for him/her (note 
that study should be started at or before noon).  If patient cannot be 
on study today, ask if he/she would be okay doing it tomorrow (start 
at Section 2.b.iii again) 
e) If multiple patients eligible on the same day, start study on one patient 
first, and then return to the other patient the next day (start at Section 
2.b.i). 
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3) Assessment #1 – Baseline before intervention #1 (Research RN and 
Research RT, estimate 30 minutes) 
a) Page research RT 
b) At the time when patient is ready to start the interventions, research 
RN will print the study order form and include in chart. 
c) Research RN will work with patient and family to complete the 
assessment #1 study forms, and perform vitals assessments and 
focused respiratory and cardiac examination 
i) Appendix A - Patient Demographics and Baseline Characteristics 
ii) Appendix C - Numeric Rating Scale for Study Assessments 
iii) Appendix D - Modified Borg Scale for Study Assessments 
iv) Appendix E - Cancer Dyspnoea Scale 
v) Appendix J - Patient Reported Adverse Effect Form 
d) Research RN will provide research RT with randomization code to 
decide which intervention would be started first. 
e) Research RT will perform the following 
i) Get equipments organized 
ii) Explain to patient how the interventions work 
iii) Answer any questions and provide reassurance 
iv) Complete assessment #1 Appendix L- Data Collection for 
Respiratory Settings 
v) Set recording trend (30, 60, 90 and 120min) for vitals assessment 
(HR, RR, BP), TCO2 and oximetry reading 
vi) Once patient and research RN all ready, start intervention #1 using 
the following parameters 
 
Vapotherm:  
Device: Vapotherm 2000i Respiratory Therapy Device  
FiO2: set at 100% 
Heat: between 35° and 37° 
Oxygen flow: titrate between 10 L/min and 40 L/min to achieve 
the highest oxygen flow to minimize dyspnea while keeping the 
patient comfortable 
 
BIPAP:  
Device: The BIPAP Vision Ventilatory Support System 
Mask: choice of nasal or face mask 
Mode: pressure support mode (S/T) 
FiO2: set at 100% 
IPAP and EPAP: started at an inspiratory pressure of 8 cm of 
H2O and expiratory pressure of 5 cm of H2O.  Titrate to minimize 
dyspnea and discomfort.  Target inspiratory pressure between 8 
and 18 cm of H2O, and target expiratory pressure between 3 
and 10 cm of H2O 
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4) Intervention #1 (Research RN and Research RT, estimate 2 hours) 
a) Once patient on stable respiratory setting, research RT will leave and 
plan to return approximately 10 minutes before termination of 
intervention #1.  During this time, research RT will be available by 
pager. 
b) Research RN may also leave after completion of assessment #1 after 
notifying unit nurses to keep an eye on patient and to page her/RT if 
needed. 
c) Research RN will return after 1 hour of intervention (±10 minutes) to 
see how the patient is doing.  If patient in distress, notify RT.  
Otherwise, leave and return approximately 10 minutes before 
termination of intervention #1.   
d) Anytime during the study, patients who could not tolerate an 
intervention because of discomfort will be offered the opportunity to 
i) Temporarily halt the intervention (back to supplemental O2) and 
resume when ready.  Research RT will be paged ASAP, complete 
appendix L. 
ii) Switch to alternative intervention after a variable washout period (if 
only tried first intervention – go to section 4. Research RN will 
complete Appendix K and research RT will complete Appendix L). 
OR 
iii) Discontinue the study and go back to supplemental O2.   Research 
RT will be paged ASAP.  Research RN will complete Appendix K 
and research RT will complete Appendix L. 
e) If patients require any breakthrough opioids (parenteral, oral, 
inhaled), breakthrough steroids (parenteral, oral or inhaled) or 
scheduled/breakthrough bronchodilators, they will need to come off 
study.  Research RN and research RT will be paged by unit RN, fill out 
Appendix K and L, respectively. 
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5) Assessment #2 (Research RN and Research RT, estimate 10 minutes) 
a) Both research RN and research RT will return approximately 10 
minutes before conclusion of intervention #1.  If one or the other not 
available, page each other ASAP (or their backups). 
b) During the next 5-10 minutes, research RN will work with patient and 
family to complete the assessment #2 study forms before research RT 
stops intervention #1. 
i) Appendix C - Numeric Rating Scale for Study Assessments 
ii) Appendix D - Modified Borg Scale for Study Assessments 
iii) Appendix F - Global Symptom Evaluation 
iv) Appendix J - Patient Reported Adverse Effect Form 
v) Appendix K - Data Collection for Assessments 
c) Research RT will complete assessment #2 Appendix L - Data 
Collection for Respiratory Settings 
d) Upon completion of all assessments, research RT will stop intervention 
#1 and put patient back on baseline intervention (same as prior to 
study).   
e) Go to washout period (Section 6). 
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6) Washout period and assessment #3 (Research RN and Research RT, 
estimate 10 minutes to 1 hour) 
a) Research RT may leave if patient stable, but will be paged back if and 
when patient ready to start intervention #2. 
b) Research RN will check if patient returns to close to baseline level of 
dyspnea using Appendix I every 10 minutes (e.g. if patient’s baseline 
dyspnea is 5, then he/she has to be at least 4 or above to start next 
intervention). 
c) Once patient is ready for next intervention, research RN will page 
research RT back ASAP. 
d) In the meantime, research RN will complete assessment #3 with 
patient 
i) Appendix C - Numeric Rating Scale for Study Assessments 
ii) Appendix D - Modified Borg Scale for Study Assessments 
iii) Appendix J - Patient Reported Adverse Effect Form 
e) Research RT will perform the following: 
i) Get equipments  organized 
ii) Explain to patient how the interventions work 
iii) Answer any questions and provide reassurance 
iv) Complete assessment #3 Appendix L- Data Collection for 
Respiratory Settings 
v) Set recording trend (30, 60, 90 and 120min) for vitals assessment 
(HR, RR, BP), TCO2 and oximetry reading 
vi) Once patient and research RN all ready, start intervention #2 using 
the following parameters 
 
Vapotherm:  
Device: Vapotherm 2000i Respiratory Therapy Device  
FiO2: set at 100% 
Heat: between 35° and 37° 
Oxygen flow: titrate between 10 L/min and 40 L/min to achieve 
the highest oxygen flow to minimize dyspnea while keeping the 
patient comfortable 
 
BIPAP:  
Device: The BIPAP Vision Ventilatory Support System 
Mask: choice of nasal or face mask 
Mode: pressure support mode (S/T) 
FiO2: set at 100% 
IPAP and EPAP: started at an inspiratory pressure of 8 cm of 
H2O and expiratory pressure of 5 cm of H2O.  Titrate to minimize 
dyspnea and discomfort.  Target inspiratory pressure between 8 
and 18 cm of H2O, and target expiratory pressure between 3 
and 10 cm of H2O 
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7) Intervention #2 (Research RN and Research RT, estimate 2 hours) 
a) Once patient on stable respiratory setting, research RT will leave and 
plan to return approximately 15 minutes before termination of 
intervention #2.  During this time, research RT will be available by 
pager. 
b) Research RN may also leave after completion of assessment #2, and 
notify unit nurses to keep an eye on patient, then page her/RT if 
needed. 
c) Research RN will return after 1 hour of intervention (±10 minutes) to 
see how the patient is doing.  If patient in distress, notify RT.  
Otherwise, leave and return approximately 15 minutes before 
termination of intervention #2.   
d) Anytime during the study, patients who could not tolerate an 
intervention because of discomfort will be offered the opportunity to 
i) Temporarily halt the intervention (back to supplemental O2) and 
resume when ready.  Research RT will be paged ASAP, complete 
appendix L. 
ii) Discontinue the study and go back to supplemental O2.   Research 
RT will be paged ASAP.  Research RN will complete Appendix K 
and research RT will complete Appendix L. 
e) If patients require any breakthrough opioids (parenteral, oral, 
inhaled), breakthrough steroids (parenteral, oral or inhaled) or 
scheduled/breakthrough bronchodilators, they will l need to come off 
study.  Research RN and Research RT will be paged, fill out Appendix 
K and L, respectively. 
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8) Assessment #4 (Research RN and Research RT, estimate 15 minutes) 
a) Both research RN and research RT will return approximately 15 
minutes before conclusion of intervention #2.  If one or the other not 
available, page each other ASAP (or their backups). 
b) During the next 10 minutes, research RN will work with patient and 
family to complete the assessment #4 study forms before research RT 
stops intervention #2. 
i) Appendix C - Numeric Rating Scale for Study Assessments 
ii) Appendix D - Modified Borg Scale for Study Assessments 
iii) Appendix G - Global Symptom Evaluation and Study Evaluation 
iv) Appendix H - Patient Preference Survey (done after patient back 
on supplemental oxygen) 
v) Appendix J - Patient Reported Adverse Effect Form 
c) Research RT will complete assessment #4 Appendix L - Data 
Collection for Respiratory Settings 
d) Upon completion of all assessments, research RT will stop intervention 
#2 and put patient back on baseline intervention (same as prior to 
study).   
e) Study completed.  Research RN and research RT sign over the clinical 
RT.  No further followup.  Resume all medications as per prior to study. 
f) Thank patient, unit RN and clinical RT 
g) Patient has the opportunity to return to baseline oxygen delivery, or 
use BiPAP or Vapotherm if agreed by with attending team 
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D. Study Budget 
 
BUDGET 
A. Personnel 
 (Indicate percent effort, salary, and names 
of personnel) 
Year 1 Year 2 Year 3 
Respiratory therapists $0 (dept)   
Research RN $0 (dept   
Data coordinator $0 (dept   
Fringe Benefits Total    
Category Total $0   
B. Permanent Equipment (Itemize) 
   
Sentec Digital Monitoring System  
  
$9,700.00 
  
Category Total $9,700.00 
  
C. Supplies (Group into major 
categories) 
   
CPAP Mask (50 units) 
 
$1550.00 
  
CPAP tubing (50 units) 
 
$485.00 
  
O2 filter (50 units) 
 
$101.00 
  
Vaportherm Filter & Setup (50 units) $6,745.00 
  
Sentec Digital Monitoring System supplies 
(50 units) 
$3180.00   
Category Total $12655.00 
  
D. Travel (DoD. Travel (Domestic only) 
   
    
Category Total $0   
E. Miscellaneous 
 (List specific amounts for each item)  
   
    
Category Total $0   
F. SUBCONTRACTS (CATEGORIZE ON 
CONTINUATION PAGE) 
   
Category Total 
   
Total Direct Costs  $21761.00   
G. Indirect Costs:       %) (Excluding 
permanent equipment) 
Total Indirect Costs 
$0   
TOTAL ANNUAL COSTS  
H. Total Amount Requested 
(Sum of all years including indirect 
costs; transfer this   amount to the budget 
section of the on-line form) 
$21761.00 
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